DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here
Colorectal cancer
Disease landscape and forecast

Treatment becoming increasingly segmented
Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on which the tumor is located, BRAF status, and MSI-H or dMMR status. Immune checkpoint inhibitors targeting MSI-H / dMMR metastatic colorectal cancer are experiencing uptake and influencing current treatment algorithms. Therapies targeting specific biomarker-defined populations, such as BRAF-mutant metastatic colorectal, contribute to more-personalized treatment.

What does the future hold for the colorectal cancer market?

Download the key insights to understand:

  • Current market dynamics
  • Market constraints
  • Current treatment dynamics
  • Unmet needs
  • Emerging pipeline drugs
Key Insights – Colorectal Cancer
Key questions answered in this report
  • What is the size of the drug-treatable colorectal cancer population, and how will drug-treatment rates change over time?
  • What are the most promising agents in the pipeline, and how will they shape the future of the colorectal cancer market?
  • What are the drivers and constraints in the colorectal cancer market, and how will the market evolve over the forecast period?

If you’d like to see these insights for other markets, visit our report store to see our full range

Note – if your company has a DRG subscription you may be able to access this report by logging in, click here.